Vitamin K2 Impairment by Common Drugs May Cause CVD

Statins and warfarin shown to share mechanism that causes CVD, Diabetes

OSLO, NORGE and METUCHEN, NJ (23 June 2016) A new review paper published in leading journal, Pharmacology, examines the positive associations observed between cardiovascular disease (CVD) and type 2 diabetes mellitus (DM), and the negative effect of medications prescribed to both groups of patients share a common mechanism: to inhibit vitamin K2-dependent processes, which was interpreted to lead to increased onset of CVD, DM, chronic kidney disease, bone fracture, and even mental disorder.

The authors of the review paper1, “Medicines and Vegetable Oils as Hidden Causes of Cardiovascular Disease and Diabetes,” note that impaired vitamin K2-dependent processes by some types of vegetable oils and medicines, but not plasma high low-density lipoprotein cholesterol, were proposed as the cause of CVD, DM and other lifestyle-related diseases.

“Once again the scientific community recognizes that the inhibition of vitamin K2 synthesis by common medications carries serious, newly recognized repurcussions,” says Hogne Vik, chief medical officer with NattoPharma, the world leader in vitamin K2 research and development, adding that while it has been well known for some time that statins inhibit CoQ10, a 2015 review paper2 finally highlighted that statins also inhibit K2 synthesis. ”Recognized Vitamin K2 antagonists significantly inhibit Vitamin K activity outside the liver with serious, unintended consequences.”

The function of K vitamins is unique among other vitamins and important throughout all life stages. Vitamin K2 activates proteins that are made in different organs in the body – clotting factors in the liver, osteocalcin in bones, and Matrix Gla Protein (MGP) in the vasculature. These proteins help coagulate blood, bind calcium to the surface of bones, and keep calcium from depositing in the arteries and soft tissues.

While the function of Vitamin K2 is vital to ensuring that the body properly utilizes calcium, studies have shown that 97 percent of Western populations are Vitamin K2 deficient/insufficient.3

“We are not only finally seeing recognition that Vitamin K2 is woefully insufficient in the diet, but the is a growing body of evidence that pharmaceuticals further exacerbate the problem of our limited Vitamin K2 status, delivering potentially dangerous consequences for human health,” Vik continues.

# # #

About MenaQ7®

MenaQ7® is the best documented, commercially available vitamin K2 as MK-7 with guaranteed actives and stability, clinical substantiation, and international patents granted and pending. MenaQ7® is available in two varieties: natural vitamin K2 as MK-7 Crystals and nature-identical synthetic vitamin K2 as MK-7 PURE. For more information on the health benefits of MenaQ7, visit menaq7.com.

About NattoPharma

NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, and has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPahrma USA, Inc., in Meuchen, NJ. For more information, visit nattopharma.com.

References:

1 Okuyama H et al. Medicines and Vegetable Oils as Hidden Causes of Cardiovascular Disease and Diabetes. Pharmacology 2016;98:134–170. DOI: 10.1159/000446704.

2 Okuyama H et al. Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms. Expert Rev Clin Pharmacol. 2015 Mar;8(2):189-99. doi: 10.1586/17512433.2015.1011125. Epub 2015 Feb 6.

3 Shea MK et al. Circulating uncarboxylated matrix gla protein is associated with vitamin K nutritional status, but not coronary artery calcium, in older adults. J Nutr. 2011 Aug;141(8):152934.

 

myHealthbox al Pharmintech di Bologna

myHealthbox presenterà le sue soluzioni innovative di eLeaflet al Pharmintech di Bologna dal 13 al 15 Aprile 2016.

Tramite il nuovo display interattivo della Corepixx sarà possibile provare dal vivo tutte le nuove funzionalità della nostra offerta eLeaflet.

Vieni a trovarci al Padiglione 22 Stand B88

myHealthbox at Pharmintech, Bologna

myHealthbox will be presenting its eLeaflet solution at Pharmintech in Bologna from the 13th to the 15th of April 2016.

You will be able to try out most of our services live through a new interactive screen provided by Corepixx.

Come meet us at Area 22 Stand B88

myHealthbox presents its multi-language eLeaflet solution at Cosmopack, Bologna

It is now common in our society that different ethnic groups and languages meet and coexist in the same country, in Italy alone there are now more than 5 million people that speak a primary language that is different from Italian (Romanian, Albanian and Arabic are amongst the most spoken). To these language minorities we can then add turists and travellers that live in Italy and speak one of the main European languages (English, Spanish and German are the main ones).

It is easy to see how, when the is a need to read information about the use of medicines of healthcare products (for example the dosage) these people would prefer reading information in their native language which they consider “safer” as less subject to interpretation errors.

Moreover there are in the world dozens of situations where 2 or more official languages are present in the same country (i.e. German in the Alto Adige region in Italy or French and Dutch in Belgium).

In Italy for example there is a requirement, for product sold in the Alto Adige region, for providing patient information in Italian and in German; until recently compliance was achieved by providing two printed versions of the patient information leaflet inside the packaging,today an alternative solution is available by making available a digital versions of the leaflet in German language via web or mobile, these can be also easily printed in the pharmacy upon request.

To provide an answer to these crucial requirement in today’s healthcare communication myHealthbox has extended its eLeaflet product with native support for 35 languages.

The use of myHealthbox as the digital leaflets distribution platform, the data security solutions implemented (both at leaflet and platform level) and the possibility of providing this information also via a QR code printed on the packaging make myHealthbox the solution of choice for those companies that need to satisfy government requirements for selling healthcare product in bi- or multi-lingual regions like Alto Adige in Italy.

To find out more visit us at Cosmopack in Bologna or contact us at sales@myhealthbox.eu

myHealthbox presenta la soluzione eLeaflet con supporto multilingua al Cosmopack di Bologna

Oggi più che mai viviamo in una realtà dove diverse etnie e lingue si incontrano e convivono nello stesso paese, solo in Italia si contano più di 5 milioni di persone che non hanno l’italiano come lingua principale (Romeno, Albanese e Arabo sono le lingue principali) oltre naturalmente a turisti e persone che sono presenti in Italia per lavoro e che parlano una delle altre lingue Europee (Inglese, Spagnolo e tedesco sono le principali).

Si può facilmente capire come, quando si tratta di leggere informazioni sull’uso di medicinali o prodotti per la salute (ad es. la posologia di una farmaco), queste persone preferiscano usare la propria lingua nativa che ritengono istintivamente più “sicura” e meno soggetta ad errori di interpretazione.

Ci sono poi nel mondo decine di realtà dove 2 o più lingue ufficiali coesistono all’interno dello stesso paese (come ad esempio la lingua Tedesca in Alto Adige o Francese ed Olandese in Belgio).

In Italia esiste l’obbligo, per i farmaci venduti in Alto Adige, di fornire le informazioni per il paziente sia in Italiano che in Tedesco; fino a poco tempo fa esistevano 2 versioni cartacee del foglio illustrativo, oggi è possibile utilizzare versioni digitali del foglio in Tedesco disponibili sia tramite web e mobile che stampabili in farmacia su richiesta.

A tutte queste esigenze ha risposto myHealthbox con il suo prodotto eLeaflet che include il supporto nativo per oltre 35 lingue.

La distribuzione dei fogli illustrativi digitali attraverso la piattaforma myHealthbox, le soluzioni di sicurezza dei dati implementate (sia a livello di formato che di piattaforma) e la possibilità di accedere a queste informazioni anche tramite un QR code sulla confezione permettono di ottemperare a tutti i requisiti stabiliti dal Ministero della Salute e da AIFA in termini di soluzioni per il bilinguismo sia specificatamente per la regione Alto Adige che per altre regioni.

Per saperne di più potete venire a visitare in nostro stand al Cosmopack di Bologna o contattarci via email all’indirizzo sales@myhealthbox.eu

myHealthbox al Cosmopack di Bologna

myHealthbox presenterà le sue soluzioni innovative di eLeaflet al Cosmopack di Bologna dal 17 al 20 Marzo 2016.

Tramite il nuovo display interattivo della Coolpix sarà possibile provare dal vivo tutte le nuove funzionalità della nostra offerta eLeaflet.

Vieni a trovarci al Padiglione 20 Stand E30

myHealthbox at Cosmopack, Bologna

myHealthbox will be presenting its eLeaflet solution at Cosmopack in Bologna from the 17th to the 20th of March 2016.

You will be able to try out most of our services live through a new interactive screen provided by Coolpix.

Come meet us at Area 20 Stand E30

myHealthbox adds support for medicine compliance monitoring

myHealthbox launches a new fully-digital medication adherence monitoring solution.

In medicine, compliance (also adherence or therapeutic adherence) describes the degree to which a patient correctly follows medical advice.

When we refer specifically to Medication Adherence we can say that this occurs when a patient takes their medications according to the prescribed dosage, time, frequency, and direction.  A breakdown in any one of these elements (missing doses, misinterpreting directions for use, or abandoning therapy altogether) is called non-compliance and has the potential to result in unanticipated side effects and complications including re-hospitalization.

Studies published in the New England Journal of Medicine showed that:

  • Half of all patients do not take their medications as prescribed (with varying degrees of non-compliance)
  • More than 1 in 5 new prescriptions go unfilled
  • Adherence is lowest among patients with chronic illnesses (but patients with chronic illnesses are also the easiest to monitor as they make repeated visits to the doctor or pharmacy where compliance can be verified and discussed).

Both the patient and the health-care provider affect compliance, and a positive physician-patient relationship is the most important factor in improving compliance.

When a direct patient-care provider relationship is missing (like for OTC medications for example) clear instructions covering how to use the medicine and complete information about the risks of non compliance are the main factors that can affect compliance either in a positive or negative way.

Medication non-adherence has long been a major issue for health and healthcare costs. According to one study, “Patient non-adherence to prescribed medications is associated with poor therapeutic outcomes, progression of disease, and an estimated burden of billions per year in avoidable direct health care costs.”

A substantial and growing body of evidence supports the, intuitive, notion that patients who adhere to their medication regimen have better health outcomes and lower total healthcare spending. For example, one study from 2011 showed that average benefit-cost ratios associated with patient adherence ranged from 3.1:1 to 10.1:1 for the chronic health conditions measured, with beneficial effects of adherence more pronounced (3.8:1 to 13.5:1) in older patients across most conditions studied.

Despite this mounting evidence, overall average drug adherence in the United States is poor, especially with therapies used to treat chronic and costly medical conditions—the conditions that plan sponsors are particularly concerned about. Evidence supporting overall dismal adherence abounds. For example, one study found that only 51 percent of patients treated for high blood pressure were adherent to their prescribed treatment.

Hospitalizations, re-hospitalizations and nursing-home admissions are recognized as direct costs of medication non-adherence in the elderly. However medication non-adherence in the elderly may also result in disease progression. It is obviously very difficult to monitor and estimate the costs of non-compliance for all OTC medications or prescription drugs that do not require mid- or end-of therapy checks by the care provider (in most cases a doctor or a pharmacists).

Among the main reasons for poor medication compliance are: avoidance of troublesome side effects, poor understanding of the medication, forgetfulness, cognitive decline, intentional under-dosage, economic limitations. It needs to be noted that these are not dependent on the type of medicine be it expensive medications for chronic diseases or over the counter drugs.

New progress in personalized medicine and digital health has exciting potential to significantly reduce costs and improve the health for those with chronic medical conditions like asthma, depression, diabetes and HIV/AIDS. While some obstacles for medication adherence may be difficult to overcome, like the high cost of many medications, others may be surmounted through technology and new partnerships.

These digital solutions have overlooked the issue of non-compliance when related to OTC and low-cost prescription medications as these solutions tend to be fairly expensive and thus applicable only to cases where either the drug is already very expensive or the costs of non-compliance is very high and can be in some way estimated.

The fact is that medication adherence is a complex public health challenge, and while better adherence can improve health outcomes and lower overall health care costs, for both patients and payers, evidence of a working solution, either digital or not, has yet to be provided.

The top digital solutions to improving medication compliance

There are a number of approaches to trying to solve this problem, some of these are:
– Gamification (Mango Health app.) and Play-it Health
Proteus Digital Health’s ingestible sensor
Pill box reminders and digital pillbox solutions
In-pharmacy monitoring services.

Under a typical medication adherence monitoring program (whether carried out at he point of sale/pharmacy or at the care provider or remotely), patients and/or providers are alerted to probable instances of non-adherence and encouraged to use the drug therapy as prescribed.

The top questions to ask a medication compliance monitoring solution

Despite recognition of a valuable problem affecting both personal health and companies budgets the big questions remains:

  • Can Digital Health Solutions really improve Medication Adherence?
  • Can they be low cost? Or better are they cost effective in any scenario?
  • Can they be easily applied to any medication?
  • Can they cover the educational part besides any scheduling and monitoring functionalities ?

The myHealthbox solution

While many companies and solutions are looking at medication adherence for chronic diseases and for patients with complex and multi-medications schedules most fail to understand that helping patients understand the specific product and monitoring compliance must be part of the same solution. A cost-effective solution must applicable in any cost and market scenario.

For example few talk about medication adherence when looking at antibiotic therapies but in fact poor adherence for these drugs is one of the major causes of an increasing poor response to antibiotics in young populations, antibiotics abuse, poor eradication of bacterial infections at the end of a therapy and eventually increasing indirect health costs.

To better address these needs myHealthbox is now offering an easy and affordable solution to monitor compliance that integrates its eLeaflet product with an easy-to-use scan and monitor digital service that can be easily integrated into any product physical packaging.

This is what make the compliance monitoring solution by myHealthbox unique :

  • it integrates seamlessly into the secure myHealthbox platform used by millions of people worldwide
  • it does not require a dedicated mobile app.
  • it does not require additional, costly hardware
  • it integrates easily into any physical packaging with minimal costs.

To know more about the myHealthbox platform and our non-compliance monitoring solution please contact sales@myhealthbox.eu

myHealthbox extends its coverage to China

myHealthbox continues extending coverage for official information on all medicines and healthcare products available on the planet by adding support for products available in China.

Information on medicinal products and offical information leaflets are already available and searchable through all myHealthbox clients and to third parties via the myHealtbox web API.

This addition brings the total number of countries supported by the myHealthbox platform to 51.